{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-063793","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.611279+00:00","generated_at":"2026-05-18T12:14:43.294756+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Traws Pharma submits Phase 2 protocols for bird flu and COVID drugs; requests FDA meeting","bullets":["Submitted HREC Phase 2 protocol for tivoxavir marboxil (TXM) to treat H5N1 bird flu and seasonal influenza.","Submitted Type D FDA meeting request to discuss accelerated approval for TXM under the Animal Rule.","Submitted HREC Phase 2 protocol for ratutrelvir in acute COVID, including PAXLOVID-ineligible patients, with rebound and Long COVID assessments.","Cash and equivalents of $15.9M as of March 31, 2025, expected to fund operations into Q1 2026.","Continuing discussions with BARDA regarding strategic stockpile inclusion for TXM."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-063793","json":"https://secwatch.observer/filing/0001104659-25-063793.json","markdown":"https://secwatch.observer/filing/0001104659-25-063793.md","text":"https://secwatch.observer/filing/0001104659-25-063793.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925063793/0001104659-25-063793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925063793/tm2519404d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T12:14:43.294756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}